PhUSE is delighted to announce that the forthcoming Computational Science Symposium with the Food and Drug Administration is open for registration.
This meeting is a unique opportunity to be informed of the latest updates and current initiatives from the FDA, industry, and academia. This is the 3rd Annual Meeting and will build on the progress made at previous events. There will be opportunities to establish collaborative working groups that address current challenges relating to the access and review of data. The ability to enhance current models to efficiently acquire, store, and analyze the data will be at the heart of the meeting agenda.
PhUSE is delighted to confirm that Charles Cooper, MD, and Steve Wilson, DrPH, of the FDA will be welcoming delegates to the Symposium alongside other representatives of CDER & CBER. In addition, a representative from CDISC will be presenting the latest updates to the data standards models. The program will then be organised into six working groups which will allow delegates to work together to discuss real world issues and how to solve them. . The working groups’ steering committee has been meeting regularly to develop an overall process and structure for the groups. Each group has co‐leads that have produced a high level list of potential topics for discussion. Unlike other forums, this event is a ‘hands‐on’ meeting that will enable those who work most closely with clinical data to debate, comment on and develop new innovative working solutions to some of theindustry’s challenges.
Ben Szilagyi , PhUSE Industry Links Director stated, “This is a great opportunity for our industry to share our expertise, know‐how, and energy to come up with novel solutions for improving the product development process. We are excited to partner with the FDA on these working groups and are looking forward to a great event.”
For registration, please follow the link: http://www.phuse.eu/ssreg.aspx
PhUSE is an independent, not‐for‐profit organization run by volunteers. Since its inception, PhUSE has expanded from its roots as a conference for European Statistical Programmers, to a global platform for the discussion of topics encompassing the work of Data Managers, Biostatisticians, Statistical Programmers, and eClinical IT professionals.
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
FDA-Approved Gene Therapy Beqvez Shows Sustained Efficacy, Safety in Long-Term Hemophilia B Trial
April 17th 2025Beqvez (fidanacogene elaparvovec), an FDA-approved one-time gene therapy for hemophilia B, demonstrated sustained factor IX expression, low bleeding rates, and a favorable safety profile over long-term follow-up.